{"brief_title": "Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder", "brief_summary": "The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.", "condition": "Depressive Disorder", "intervention_type": "Drug", "intervention_name": "Duloxetine Hydrochloride", "criteria": "Inclusion Criteria: - Signed the informed consent - Meet criteria for major depressive disorder without psychotic features. - Have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel. - Have had at least one other major depressive episode prior to the one being experienced at study entry. - You are reliable and agree to keep all appointments for clinic visits, tests and procedures required by the protocol. Exclusion Criteria: - You have had treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry. - Any women who are pregnant or breast feeding. - If you have any serious medical illnesses other than major depressive disorder. - If you have previously participated in a clinical trial for duloxetine. - Any previous or current diagnosis of bipolar, schizophrenia, or other psychotic disorders.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00036309.xml"}